Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07078591
PHASE2

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

Sponsor: Beijing 302 Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).

Official title: Phase 2 Study of Venetoclax-containing Therapy in Combination With HLA-mismatched Mobilized Peripheral Blood Mononuclear Cell Infusion for Newly Diagnosed Acute Myeloid Leukemia

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2025-06-20

Completion Date

2031-06

Last Updated

2025-07-28

Healthy Volunteers

No

Interventions

DRUG

Venetoclax

Given PO

DRUG

Azacitidine (AZA)

Given SC

DRUG

Daunorubicin

Given IV

DRUG

Idarubicin(IDA)

Given IV

DRUG

Cytarabine (Ara-C)

Given IV

BIOLOGICAL

GPBMC infusion

HLA-mismatched donor GPBMC infusion

Locations (1)

Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital

Beijing, China